Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Northrop Grumman enters the final two weeks before its October 20 earnings report down 8% on the month, with the Street divided and options traders showing less anxiety than they did a week ago, despite the stock making fresh lows.
The options picture has shifted noticeably. Put/call ratio has eased further to 1.11, now running fractionally below its 20-day average of 1.15. The z-score of -0.70 marks the least defensive options posture in several weeks. That is a meaningful change from the peak alarm of late September, when the PCR touched the 52-week high of 1.29. Hedging demand has receded even as the stock dropped a further 2% on the week to $473.46. Whether that reflects exhaustion in put buying or genuine calm is the open question heading into the print.
The borrow market adds no pressure from the short side. Short interest is a thin 1.6% of free float, unchanged in direction, with the week-on-week move barely above 1%. Borrowing costs have dropped sharply, falling 38% on the week to just 0.30%, their lowest level in the 30-day window. Availability is effectively uncapped. The lending market is not signalling any fresh conviction from bears, and it has not done so all year.
The Street remains split and the gap between price and consensus is the most striking data point. Rothschild initiated at Buy with a $680 target on October 6, pushing against the RBC downgrade from four days earlier, where Ken Herbert cut to Sector Perform and slashed his target from $640 to $525. Those two moves frame the debate cleanly. The consensus mean target of $634 now sits 34% above the current price of $473. Bulls cite the B-21 and Sentinel programs moving from development into production, a roughly $35 billion Defense Systems backlog, and management's plan to double international sales to around $10 billion by 2031. Bears counter that top-line growth of around 6% through 2028 is already priced in, that cumulative B-21 fixed-price losses have reached roughly $2 billion, and that the loss of the Navy's F/A-XX contract removes a potential re-rating catalyst. The PE has compressed to 15.7x over the past month, down from closer to 17x thirty days ago, while EV/EBITDA has eased to 12.2x.
On the ownership side, the Vanguard picture is worth a glance. The original Vanguard Group entity filed a 13G/A in March showing its stake falling to 0%, down from 9.16% previously. A separate Vanguard Capital Management entity filed its own 13G in April showing a 7.22% position. The institutional data shows Vanguard Capital Management holding 9.75 million shares as of August. This appears to reflect a restructuring of how Vanguard's funds are reported rather than a genuine exit, but readers should note the disclosure caveat: 13D/G stakes are event-driven filings around the 5% threshold, and positions are as last disclosed. BlackRock added just over 900,000 shares in the latest reported period, T. Rowe Price added over 1.2 million shares, and Mirae Asset added 487,000 shares, none of these are dramatic moves but the direction is modestly constructive among the top holders.
Wikipedia attention is running well above its own 90-day baseline, with a z-score of 2.69 as of October 1. That is a retail attention signal, not a revenue indicator, but it does suggest the stock is drawing more public interest than usual in the weeks before the print. The next 12 days will tell whether that attention reflects concern about the fixed-price program losses or renewed interest in the defense franchise.
See the live data behind this article on ORTEX.
Open NOC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
